Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Lawyers representing ovarian cancer victims are urging a NO vote on Johnson & Johnson's (NYSE:JNJ) latest $6.5 billion bankruptcy settlement plan. They claim J&J is misleading potential claimants and attempting to secure approvals from individuals without documented ovarian cancer diagnoses. The attorneys argue this strategy could reduce payments to legitimate victims who have incurred losses of $500,000 or more.
The deadline for voting on the bankruptcy proposal is July 26, 2024. Opponents of the plan note that approval would eliminate rights to a jury trial for current and future victims. Since 2016, juries have awarded over $5.4 billion in damages to ovarian cancer claimants, although this amount has been reduced in subsequent court proceedings.
Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking approval of SPRAVATO® (esketamine) as a monotherapy for adults with treatment-resistant depression (TRD). This submission is based on positive results from the Phase 4 TRD4005 study, which showed rapid improvement in depressive symptoms as early as 24 hours after the first dose, sustained through at least 4 weeks of treatment. The safety profile was consistent with existing clinical data.
SPRAVATO® is currently approved in combination with an oral antidepressant for TRD and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. It has been approved in 77 countries and administered to over 100,000 people worldwide. This new application aims to expand its use as a standalone treatment for TRD, potentially offering a new option for patients who have not responded adequately to multiple oral antidepressants.
Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.24 per share for the third quarter of 2024. The dividend will be payable on September 10, 2024 to shareholders of record at the close of business on August 27, 2024. The ex-dividend date is also set for August 27, 2024. This announcement demonstrates JNJ's commitment to returning value to shareholders through consistent dividend payments.
Johnson & Johnson (NYSE: JNJ) reported strong Q2 2024 results with reported sales growth of 4.3% to $22.4 Billion and adjusted operational growth of 6.5%. The company's EPS decreased by 5.9% to $1.93 due to one-time special charges, while adjusted EPS increased by 10.2% to $2.82.
Key highlights include:
- Robust pipeline progress with TREMFYA, RYBREVANT, and VARIPULSE
- Increased full-year 2024 operational sales guidance reflecting Shockwave Medical acquisition
- Updated full-year 2024 adjusted operational EPS guidance
- Strong performance in Innovative Medicine and MedTech segments
The company's focus on medical innovation and strategic acquisitions positions it for continued growth.
Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Yellow Jersey Therapeutics, a subsidiary of Numab Therapeutics, for $1.25 billion. This acquisition secures JNJ the global rights to NM26, a novel, investigational bispecific antibody targeting IL-4Rα and IL-31 pathways in atopic dermatitis (AD). NM26 is ready for Phase 2 clinical trials and aims to provide better treatment for AD by addressing multiple disease-driving pathways. The investment aligns with JNJ's mission to improve care for immune-mediated diseases.
Johnson & Johnson (NYSE: JNJ) announced positive results from an interim analysis of the Phase 3 CARTITUDE-4 study, which evaluated CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) against standard therapies for treating multiple myeloma in patients who have had one prior line of therapy. The study showed that CARVYKTI® achieved a statistically significant and clinically meaningful improvement in overall survival (OS) compared to standard treatments like PVd and DPd. The safety profile was consistent with the approved label. These results will be shared at an upcoming medical meeting and submitted to regulatory authorities.
Johnson & Johnson announced positive results from the Phase 3 Vivacity-MG3 trial of nipocalimab in patients with generalized myasthenia gravis (gMG). The study showed that patients treated with nipocalimab plus standard of care (SOC) improved significantly more than those on placebo plus SOC in the MG-ADL score over 24 weeks. The trial included a broad range of gMG patients, representing 95% of the population. Key secondary endpoints, including muscle strength and function, also showed significant improvements. Safety and tolerability were consistent with prior studies. These findings will be presented at the EAN 2024 Congress and submitted to regulatory authorities.
The U.S. Supreme Court has denied Purdue Pharmaceuticals' $7 billion bankruptcy plan, which sought to grant the Sackler family immunity from further liability for their role in the opioid crisis. This decision has significant implications for Johnson & Johnson (NYSE:JNJ), which is attempting to use bankruptcy protection to resolve tens of thousands of ovarian cancer claims related to its talc-based products.
The Beasley Allen Law Firm, representing the plaintiffs in the talc/ovarian cancer multidistrict litigation (MDL), believes this ruling undermines J&J's similar attempts to use bankruptcy as a shield. The court's decision reinforces that financially solvent entities cannot use bankruptcy to escape liability for marketing and manufacturing dangerous products.
This ruling could derail J&J's efforts to return the talc litigation to bankruptcy courts, potentially moving forward with trials that support the plaintiffs' constitutional rights and address the substantial financial and emotional toll suffered by J&J’s victims.
Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Proteologix, a biotech firm specializing in bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential milestone payments. This acquisition, announced on May 16, 2024, brings two pre-clinical bispecific antibodies, PX-128 and PX-130, into J&J's portfolio. These antibodies target multiple disease pathways and could transform treatments for atopic dermatitis and asthma. Additionally, J&J gains eight other bispecific antibody programs, enhancing its capabilities in innovative immunology therapeutics.
Johnson & Johnson submitted a supplemental Biologics License Application to the U.S. FDA for TREMFYA® (guselkumab) to treat moderately to severely active Crohn's disease.
The application is based on 48-week results from Phase 3 GALAXI and GRAVITI programs.
Data show TREMFYA®, an IL-23 inhibitor, achieved superior endoscopic outcomes with subcutaneous (SC) and intravenous (IV) induction therapies.
GALAXI demonstrated TREMFYA®'s superiority over STELARA® (ustekinumab) in Crohn's disease.
Both GALAXI and GRAVITI studies met multiple co-primary endpoints, showing significant clinical remission and endoscopic response at various weeks.
If approved, TREMFYA® will be the first IL-23 inhibitor offering both SC and IV induction therapy options for Crohn's disease.
This is Johnson & Johnson's second FDA submission for inflammatory bowel disease this year, after a March submission for ulcerative colitis.